Volume 18, Issue 1 (Spring 2014)                   Physiol Pharmacol 2014, 18(1): 27-35 | Back to browse issues page

XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Hakimizadeh E, Shamsizadeh A, Vazirinejad R, Kazemi Arababadi M, Rezazadeh H, Mobini M, et al . Investigate the effect of TRPV1 receptor antagonist (AMG9810) on stroke outcome in the permanent middle cerebral artery occlusion in male rat. Physiol Pharmacol 2014; 18 (1) :27-35
URL: http://ppj.phypha.ir/article-1-954-en.html
Abstract:   (9225 Views)
Introduction: TRPV1 is a non-selective cation channel with high permeability to calcium ions, and is also involved in the development of neurogenic and inflammatory pain. The increase in intracellular calcium plays a role in worsening of stroke. In the present study we investigated the effect of (AMG9810) TRPV1 receptor antagonist on stroke outcome in the permanent middle cerebral artery occlusion model in rat. Methods: In this experimental study, a total of 24 male Wistar rats weighing 250-300g were divided into 3 groups as following: control, treatment and sham. Stroke was induced by permanent middle cerebral artery occlusion method. The animals were then treated with the TRPV1 receptor antagonist Amg9810 (0.5 mg/kg, ip) and vehicle (DMSO) 3h after stroke. Infarct volume was determined by TTC staining, and sensory motor deficits were assessed by sticky and hanging tests at 1, 3 and 7 days after stroke induction, and compared. Results: One week after stroke, Amg9810 decreased the cortical infarct volume (P< 0.05). The touch time and remove time (in sticky test) was decreased in these animals (P< 0.001) but hanging test was increased (P< 0.01). Conclusion: TRPV1 receptor inhibition may decrease infarct volume and sensory-motor deficits following stroke due to permanent middle cerebral artery occlusion in rat.
Keywords: Stroke, TRPV1, Amg9810
Full-Text [PDF 639 kb]   (1897 Downloads)    
Type of Manuscript: Experimental research article | Subject: Others

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.